|
|
|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
| Naslov: |
Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial |
| Vir: |
|
|
|
List of services to meet your request
Contains list of services for current record
|
|
|
|
|
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
|
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=s421866CE-6074-11EF-8CED-D23485CE164B&I=39IZM&T=&OP=Display&O=html&O1=15909533&O2=954925385125&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DDouble%2520Step-up%2520Dosing%2520%25282SUD%2529%2520Regimen%2520Mitigates%2520Severe%2520Icans%2520and%2520CRS%2520While%2520Maintaining%2520High%2520Efficacy%2520in%2520Subjects%2520with%2520Relapsed%252FRefractory%2520%2528R%252FR%2529%2520B-Cell%2520Non-Hodgkin%2520Lymphoma%2520%2528NHL%2529%2520Treated%2520with%2520AZD0486%252C%2520a%2520Novel%2520CD19xCD3%2520T-Cell%2520Engager%2520%2528TCE%2529%253A%2520Updated%2520Safety%2520and%2520Efficacy%2520Data%2520from%2520the%2520Ongoing%2520First-in-Human%2520%2528FIH%2529%2520Phase%25201%2520Trial%26rft.au%3DGaballa%252C%2520Sameh%26rft.date%3D2023-11-02%26rft.eissn%3D1528-0020%26rft.epage%3D1662%26rft.externalDBID%3Dn%252Fa%26rft.externalDocID%3D10_1182_blood_2023_174668%26rft.genre%3Darticle%26rft.issn%3D0006-4971%26rft.issue%3DSupplement%25201%26rft.jtitle%3DBlood%26rft.spage%3D1662%26rft.volume%3D142%26rft_id%3Dinfo%253Adoi%252F10.1182%252Fblood-2023-174668%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-ELSEVIER_SCIENCEDIRECT_AUTOLOAD_JOURNALS_UL_LCL-getFullTxt-object,2-UNPAYWALL-getFullTxt-object,3-GFMER_FREE_MEDICAL_JOURNALS-getFullTxt-object,4-DOI-getDOI-object,5-COBIB_SI_LCL-getHolding-object,6-ELSEVIER_SCOPUS_FIS_LCL-getAbstract-object,7-NCBI_PUBMED_FREE-getAbstract-object,8-ISI_WEB_OF_SCIENCE-getAuthor-object,9-ISI_JOURNAL_CITATION_REPORTS_SCIENCE_EDITION-getCitedJournal-object,10-REFWORKS_EXPORT_TOOL-getReference-object,11-SHERPA_RoMEO_LCL-getWebService-object,12-GOOGLE_SCHOLAR_FREE-getWebSearch-object,13-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=0.979822&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:15909533-s421866CE-6074-11EF-8CED-D23485CE164B" timestamp="2024-08-22T12:49:52Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:954925385125</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial</jnl:atitle>
<jnl:jtitle>Blood</jnl:jtitle>
<jnl:date>2023-11-02</jnl:date>
<jnl:spage>1662</jnl:spage>
<jnl:epage>1662</jnl:epage>
<jnl:coden>BLOOAW</jnl:coden>
<jnl:issn>0006-4971</jnl:issn>
<jnl:volume>142</jnl:volume>
<jnl:issue>Supplement 1</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>1528-0020</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:coden>BLOOAW</jnl:coden>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:5e02418cf5342b2beafb889af74a8982082d4ac2</ctx:identifier>
<ctx:identifier>urn:UUID:s421866CE-6074-11EF-8CED-D23485CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)